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OBJECTIVES: Antidepressants can cause undesirable drug-drug interactions when
taken concomitantly with certain medications. Elderly patients may be particularly 
vulnerable to antidepressant interactions due of slower metabolism and utilization 
of multiple pharmacotherapies. The objective of this study was to determine rates
of potential drug-drug interactions involving antidepressants in a geriatric population 
and their impact on prescription adherence. METHODS: Data were from the
MarketScan Medicare Database, a claims database from retirees with employer-
sponsored Medicare supplemental insurance. Subjects were age 65 years, new anti-
depressant users, and had a depression diagnosis between 7/1/2001–12/31/2006.
Potential drug-drug interactions involving at least one antidepressant and another drug
with overlapping days supplied were identiﬁ ed over the one year following antidepres-
sant initiation using MicroMedex DRUG-REAX software. Multinomial logistic 
regression and bivariate statistics were used to evaluate the association between
potential interactions and whether patients discontinued, reﬁ lled or switched their ﬁ rst 
antidepressant prescription. RESULTS: Among the 39,512 patients who met the inclu-
sion criteria, 25.4% had potential contraindicated or major interactions, 36.1% had 
moderate interactions, and 38.5% had minor or no interactions. Compared to the
moderate/minor/no interactions groups, the contraindicated/major group had a greater
prevalence of medical comorbidities and higher comorbidity indices (p  0.001).
Amitriptyline hydrochloride was involved in 19.1% of the potential contraindicated/
major interactions. Tramadol hydrochloride and oxycodone, opioid analgesics, were
the most common medications with contraindicated/major interactions. Presence of 
contraindicated/major and moderate interactions was associated with an increase
probability of switching to a different antidepressant of 23 and 11 percentage points, 
respectively (p  .001) and decreased probability of discontinuing of 3.5 and 2.5 per-
centage points (p  0.001), after controlling for age, gender, pre-period mental disor-
ders and medical comorbidities, antidepressant treatment type, and use of other 
psychotropic medications. CONCLUSIONS: Elderly antidepressant users frequently
use medications with the potential for interactions with their antidepressant medica-
tion. There is a need for antidepressants with improved interaction proﬁ les.
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OBJECTIVES: Patients prescribed a regimen of atypical antipsychotic medications face 
many challenges. Adherence and persistence rates are typically low. We investigated
determinants of adherence and persistence to second-generation antipsychotic medica-
tions (SGAs) for patients with schizophrenia and bipolar disorder, including ﬁ nancial
factors (patient cost-sharing and out-of-pocket burden) and formulary status.
METHODS: A retrospective study of patients aged 18–64 years with at least one SGA
claim, 24 months of continuous enrollment and employer-based coverage via large US
ﬁ rms in 2003–2006 (n  9714). The study initiation index date was deﬁ ned as the ﬁ rst
SGA ﬁ ll following a 12-month period without use of SGAs. Multivariate Cox propor-
tional hazards models were estimated for persistence to SGAs (using a 30-, 60- and
90-day gap in therapy) and multivariate cross-section/time-series models were esti-
mated for SGA adherence (PDC  80%). Explanatory variables included patient, plan,
and provider characteristics, health status, cost-sharing (prescription drug and medical) 
and time. An empirical measure of SGA formulary status was developed. RESULTS:
Over three quarters of patients (83%) discontinued SGA treatment and average per-
sistence until a 90-day gap was 184 days. Higher prescription drug and ofﬁ ce visit 
patient cost-sharing amounts were associated with shorter time on SGAs, especially 
when cost-sharing exceeded $40 per ﬁ ll or visit (95% conﬁ dence interval hazard ratio
for 90-day gap (1.01,1.15) prescription drug (1.00,1.24) ofﬁ ce visit) relative to cost-
sharing of $. Higher prescription drug cost-sharing and patient total (drug and
medical) out-of-pocket burden (measured in the previous 12 months) were associated 
with lower levels of adherence (both p  0.01). CONCLUSIONS: Even in a well-insured
patient population, beneﬁ t plan design factors can affect adherence and persistence to
SGAs for patients with schizophrenia and bipolar disorder. Insurers and plan managers
should take note of the prescription drug and medical plan design attributes that inﬂ u-
ence adherence to medications among this vulnerable patient group.
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OBJECTIVES: To investigate the relationship between compliance and ﬁ rst-year post-
treatment cost for patients with schizophrenia. METHODS: Commercial health plan 
data from July 1, 2003 to June 30, 2006 were used to identify patients with schizo-
phrenia who initiated treatment using a typical or atypical antipsychotic, a mood sta-
bilizer or an antidepressant. Episodes were divided into three categories: restarting 
treatment after a break in drug therapy 15 days with the drug used in the previous
episode; switching therapy with or without a break in treatment; and augmentation 
therapy. First observed episodes were excluded due to uncertainty concerning the 
patient’s prior treatment history. A total of 21,872 episodes were included in ordinary 
least squares (OLS) regression models of post-treatment cost as a function of alterna-
tive deﬁ nitions of compliance adjusting for age, gender, geographic region, drug use 
history, prior medical care use, schizophrenia diagnosis and co-morbid medical condi-
tions. RESULTS: Adding a second medication within one year is the key factor in the 
relationship between compliance and one-year costs. One year of uninterrupted 
therapy on the initial drug without adding a second medication increased drug costs 
by $3314, while reducing medical costs by $3919 (p  0.0001 for both estimates)
and total cost by $605 (p  0.05). One year of therapy on the initial drug augmented
with a second medication increased drug costs ($5062) and medical costs ($3477) 
compared to non-compliance (p  0.0001 for both estimates). One year of uninter-
rupted therapy on a second drug after terminating the initial therapy was associated 
with the highest costs: $3,955 for drugs and $8,902 for medical services (p  0.0001 
for all estimates). Analyses conducted separately by type of episode conﬁ rmed these
patterns of cost estimates. CONCLUSIONS: Compliance is associated with signiﬁ cant 
reductions in medical costs only if the patient is maintained on their initial drug
regimen. Changes in therapy are associated with higher medical costs.
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OBJECTIVES: The objective of this study was too characterize geriatric antidepressant
users’ rate of claims documented treatment-related side-effects, and their impact on
prescription-adherence and costs. METHODS: Data were from the MarketScan
Medicare Database, a de-identiﬁ ed health care database for retirees with employer-
sponsored Medicare supplemental insurance. Subjects age 65 years who were new 
antidepressant users with a depression diagnosis were identiﬁ ed between July 1, 2001-
December 31, 2006. Twelve commonly reported antidepressant side-effects were iden-
tiﬁ ed through ICD-9-CM diagnoses. Multinomial logistic regression was used to 
evaluate the effect of side-effects on adherence. RESULTS: A total of 39,512 treat-
ment-naïve antidepressants users were selected and compared to 1,144,481 non-users. 
Antidepressant users were slighter older than non-users (76.5 vs. 75.6 years, p 
0.001), more were female (63.2% vs. 52.5, p  0.001), and had higher prevalence of 
psychiatric, and non-psychiatric conditions. Approximately 5.5% (n  2214) of SSRI/
SNI users had diagnoses indicating side-effects within the ﬁ rst 30-days of treatment. 
Approximately 18% of new antidepressant users switched antidepressants, 23% dis-
continued, and 59% reﬁ lled after their ﬁ rst prescription ﬁ ll. The presence of a docu-
mented side-effect was associated with a 28.5% (4.7 percentage points) increase in 
the probability of switching and a 16.8% increase in the rate of discontinuation (3.7 
percentage points) (p  0.01). The average cost of medical and pharmaceutical treat-
ment for antidepressant side effects over the ﬁ rst month of treatment was approxi-
mately $336 (SD  $167). The cost of treating side-effects added $20.15 (1.8%) to
the total health care costs of the all antidepressant users during their ﬁ rst month after
antidepressant initiation. CONCLUSIONS: Antidepressant therapy in the elderly is 
associated with a signiﬁ cant level of side effects, which in turn is associated with lower
adherence, and greater cost of depression care. There is a need for an antidepressant 
with improved tolerability proﬁ le for the elderly to minimize non-adherence and eco-
nomic burden to payers.
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OBJECTIVES: To examine the impact of having a newly prescribed second generation 
anti-psychotic (SGA) claim rejected due to formulary restrictions on subsequent medi-
cation persistence to the SGAs. METHODS: A retrospective cohort study was con-
ducted using data from a national pharmacy beneﬁ t management company. Newly 
initiated antipsychotic users, aged 18–64 years who had a rejected SGA (aripiprazole, 
olanzapine, quetiapine, risperidone, ziprasidone) claim due to beneﬁ t reasons (step
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therapy, prior authorization, not in formulary) between January 1, 2005 to December
31, 2006 but who subsequently ﬁ lled an SGA or conventional antipsychotic within six 
months of the rejected claim, formed the case group (n  328). Newly initiated anti-
psychotic users who were in health plans with an open formulary and thus did not 
experience rejection of an SGA claim formed the control group (n  1097). All patients
were followed up for 13 months. Cox regression models were used to estimate the 
effect of having rejected claims on all-cause discontinuation of the index drug, deﬁ ned
as discontinuation, add-on or switch. The model controlled for age, sex, co-morbidities, 
geographic locations, index drug, prescription and co-payment. RESULTS: Reasons
for rejected claims were distributed as follows: 1) drug not on formulary (72.9%); 2)
required prior authorization (19.5%); and 3) required step therapy (7.6%). Median 
time to discontinuation was 120 days for the case group and 127 days for the control 
group. The adjusted hazard for discontinuation of the index drug (HR  1.29, 95% 
CI: 1.08–1.53) was signiﬁ cantly higher for patients with rejected initial SGA claims
compared to controls. Co-payments ranging from $20 to $39 were associated with
lower discontinuation compared with copayment ranging from $0 to $4 (HR  0.75, 
95% CI: 0.60–0.93). CONCLUSIONS: New antipsychotic users with rejected initial 
SGA claims due to formulary restrictions were more likely to discontinue their anti-
psychotic drugs compared to users who did not face such restrictions.
PMH45
THE ASSOCIATION OF COPAY BURDEN AND MEDICATION ADHERENCE 
AMONG PATIENTS WITH SCHIZOPHRENIA
Kim E1, Gupta S2, Bogle SC2, Chen CC1, Whitehead R3, Bates JA1
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Consumer Health Sciences, Princeton, NJ, USA, 
3Otsuka America Pharmaceutical, Inc, Rockville, MD, USA
OBJECTIVES: To assess the association between self-perceived copay burden and
medication adherence among patients with schizophrenia. METHODS: Data were 
collected from December 2007 to February 2008 from a web-based consumer panel. 
Adults (age 18) self-reporting a diagnosis of schizophrenia were invited to participate
in the study through self-reported questionnaires on both the internet and through 43 
interview facilities across the US. Inclusion criteria for analysis were: current use of 
an SGA, and no exposure to clozapine or a depot formulation antipsychotic. Adher-
ence was assessed using the MMAS, with general adherence deﬁ ned as MMAS  2, 
and complete adherence deﬁ ned as MMAS  1. Logistic regression models were
developed to assess the effects of self-perceived copay burden on adherence while
adjusting for demographics, substance use, concomitant psychotropic medications,
comorbidities, and health insurance. RESULTS: Of the 351 study respondents who 
met the criteria for analysis, 39% (n  137) perceived experiencing burden from their 
medication copays. Adjusting for covariates, the effects of copay burden on general
adherence approached but did not reach signiﬁ cance (p  0.060). However, patients
who experienced a copay burden were less than half as likely to have complete adher-
ence [OR  0.427; 95% CI: (0.257, 0.711); p  0.001]. Effects of copay burden on 
the individual components of the MMAS varied. Patients with copay burden were 
more likely to forget to take medication [OR  2.058; 95% CI: (1.270, 3.335); p 
0.003] and to discontinue medication when feeling worse [OR  2.000; 95% CI: 
(1.140, 3.507); p  0.016]. Being careless about taking medication and discontinuing
medication when feeling better were not signiﬁ cantly affected by copay burden. 
CONCLUSIONS: Among patients with schizophrenia using SGAs, copay burden is
associated with forgetting to take medication, discontinuing medication when feeling
worse, and lesser likelihood of complete adherence. Less restrictive formularies that
reduce copay burden for SGAs may have a positive effect on medication adherence 
among patients with schizophrenia.
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OBJECTIVES: Treatment of depression is often accompanied by discontinuation and
switching of antidepressant medications. Information on factors predicting persistence
(and avoidance of switching) would thus be of value to medical decision makers. We
assess the impact of demographics, initial dose, prior medications, and comorbidities
on duloxetine treatment persistence for patients with major depressive disorder
(MDD) using retrospective claims data. METHODS: Using the PharMetrics Database,
we studied individuals aged 18–64 who initiated duloxetine treatment between April 
2005 and March 2006, had q1 prior MDD diagnosis, and had continuous insurance
coverage 6 months before and 12 months after initiation. Persistence was deﬁ ned as
q3 months’ continuous duloxetine treatment. Stepwise logistic regression and tree
analyses of demographics, initial dose, prior medications, and comorbidities assessed
predictors of persistence. Sensitivity analysis was done by analyzing factors associated 
with switching to venlafaxine XR or a selective serotonin reuptake inhibitor (SSRI)
within a year of initiating duloxetine. RESULTS: Among 9,148 patients (74.1%
female; mean age  45.6, SD  11.1) who initiated duloxetine treatment, 63.5% had
persistence of duloxetine treatment for q3 months. Regression results showed the most 
signiﬁ cant factors for persistence to be initial dose of q60 mg QD (OR  1.38), age
group of 46–64 yrs (OR vs. age 18–25 yrs  1.63), and venlafaxine XR/SSRI use in 
the prior 3 months (OR  1.64) (all p-values  .001). Sensitivity analysis showed initial 
dose of 60 mg QD was associated with switching from duloxetine (OR  1.22), 
although other factors showed differences from the persistence analysis. CONCLU-
SIONS: The results suggest that for MDD patients, initial dose, age group, and recent 
venlafaxine XR/SSRI use predict persistence on duloxetine treatment. Sensitivity 
analysis on switching showed a consistent effect of initial dose.
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OBJECTIVES: To assess the reasons for discontinuation and for continuation of 
antipsychotic medication in the treatment of schizophrenia from patient and clinician 
perspectives. METHODS: Two measures were developed to assess the Reasons for
Antipsychotic Discontinuation/Continuation (RAD), one from patient’s perspective 
(RAD-I), and the other from clinician’s perspective (RAD-Q). These measures were
administered to patients enrolled in a 12-week study of antipsychotic medication in 
the treatment of schizophrenia (N  630). Reasons for discontinuation and reasons 
for continuation with the assigned antipsychotic during the study were assessed. 
Reported reasons were rated as being a primary reason, very important, somewhat 
important, or of minor importance. The top primary reasons for medication discon-
tinuation and continuation were identiﬁ ed from patient and clinician perspectives, and 
level of concordance between patients’ and clinicians’ reasons was assessed. RESULTS:
The top primary reasons for medication discontinuation differed from the top primary 
reasons for continuation on the medication, with a high level of concordance between 
patients’ and clinicians’ perspectives. The top three primary reasons for medication
discontinuation were insufﬁ cient improvement or worsening of positive symptoms, 
medication-related adverse events, and insufﬁ cient improvement or worsening of 
mood symptoms. The top three primary reasons for medication continuation were
improvement in positive symptoms, subjective perception of improvement, and 
improvement in level of functioning. CONCLUSIONS: Medication efﬁ cacy appears 
to be the core driver of medication continuation and discontinuation, especially with
regard to positive symptoms. Reasons for medication discontinuation differ somewhat 
from reasons for continuation, with a high level of concordance between patients’ and 
clinicians’ perspectives.
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OBJECTIVES: The purpose of this analysis is to quantify the additive burden associ-
ated with experiencing depression symptoms in patients with type-2 diabetes mellitus 
(T2DM). METHODS: Data were from the 2008 US National Health and Wellness 
Survey (NHWS), an annual cross-sectional survey of self-reported health care atti-
tudes, behaviors, disease states, and outcomes of adults aged 18. Analyses were 
limited to respondents self-reporting a diagnosis of T2DM. Depression symptoms were
deﬁ ned as an afﬁ rmative response in the past month to: bothered by feeling down, 
depressed or hopeless; or bothered by having little interest or pleasure in doing things.
Outcomes included health care utilization in the past six months, work productivity 
as measured by the Work Productivity and Activity Impairment (WPAI) questionnaire, 
and SF-12v2 summary scores. Logistic and linear regression models were developed
to assess independent effects of depression on outcomes, while adjusting for demo-
graphics and co-morbidity. RESULTS: Among patients with T2DM, 38% self-reported 
depression symptoms. Adjusting for demographics and co-morbidity, patients with
depression symptoms were 1.7 (p  0.001) times as likely to visit the emergency room, 
1.6 (p  0.001) times as likely to be hospitalized, and had 2.2 (p  0.001) additional 
provider visits compared to T2DM patients without depression symptoms. Depression
symptoms were also associated with 21.4% (p  0.001) greater impairment in daily
activities and a decrease in SF-12v2 physical and mental summary scores of 4.0 (p 
0.001) and 12.7 (p  0.001) points, respectively. Among patients who were employed
full-time, depression symptoms were associated with 4.3% (p  0.001) greater missed 
work time, 15.2% (p  0.001) greater lost productivity while working, and 13.4% (p
 0.001) greater overall work impairment. CONCLUSIONS: In patients with T2DM, 
depression symptoms were associated with signiﬁ cant burden on health care utiliza-
tion, work productivity, and health-related quality of life. Proper treatment of both
T2DM and co-morbid depression in this population may reduce humanistic and eco-
nomic burden of disease.
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OBJECTIVES: Type 2 Diabetes Mellitus (T2DM) is an adult-onset, chronic, metabolic 
disorder that affects approximately 23.5 million adults in the United States and 
requires management with daily medications, blood glucose monitoring, regular 
HbA1c assessments, diet, and exercise. If T2DM patients also have difﬁ culties
with planning, working memory, and organization, their health problems may 
be compounded due to inappropriate management of their chronic health condition. 
The current study sought to estimate the prevalence of T2DM patients with the 
